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rate of failures, evaluation of treatment intensification by 
systemic components maybe warranted in patients with 
recurrent soft-tissue sarcomas.  
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Purpose or Objective: To report our long-term results with 
surgery, IOERT and postoperative EBRT in patients with soft-
tissue sarcomas of the upper extremity. 
 
Material and Methods: We performed a retrospective 
analysis of 37 patients suffering from soft-tissue sarcomas of 
the upper extremity, who received surgery, IOERT and 
postoperative EBRT at our institution. Median age was 61 
years (28-83) and median tumor size was 6 cm (1-15). 26 
patients (70%) presented in primary situation. Stage at 
presentation (UICC 7th) was as follows: IIa:43%, IIb:8%, 
III:43%, IV:5%. All patients suffered from high grade lesions 
(FNCLCC G2: 27%, G3:73%), predominantly MFH (51%). Gross 
total excision was achieved in all patients with free margins 
in 51% and microscopically positive margins in 49%. IOERT was 
applied to the tumor bed with a median dose of 15 Gy, using 
electron energies of 6-8 MeV and a median cone size of 8 cm. 
All patients received postoperative EBRT with a median dose 
of 45 Gy. 30% of the patients also received pre- and/or 
postoperative chemotherapy. 
 
Results: The median follow up was 78 months (6-231) for the 
entire cohort and 94 months (6-231) in survivors. Local 
failures were observed in 6 patients (16%), resulting in 
estimated 5-year and 10-year local control rates of 80%. 9 
patients (24%) showed distant failures, transferring into 
estimated 5-year and 10-year distant control rates of 71%. 
Overall treatment failure was observed in 14 patients (38%), 
of whom 5 failed locally only, 8 distant only and 1 combined, 
resulting in 5- and 10-year estimated FFTF rates of 55%.11 
patients have deceased, transferring into estimated 5-and 10-
year overall survival rates of 82% and 70%, respectively. 
Severe postoperative complications were rare (3%). Severe 
late toxicity was found in 11% of the patients. Preserved limb 
function without impairment in activities of daily living was 
achieved in 79% of the patients. 
 
Conclusion: Combination of surgery, IOERT and postoperative 
EBRT resulted in good local control and overall survival given 
the high rate of microscopically positive resections in this 
unfavourable patient cohort. Severe postoperative 
complications were rare compared to other sites.  
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Purpose or Objective: Cardiac and large vessel sarcomas are 
extremely rare neoplasms exhibiting aggressive behavior. 
Surgery is the most widely accepted treatment modality, but 
local recurrence and metastatic spread are common.The role 
of radiation ("definitive" or adjuvant) and chemotherapy is 
poorly-defined. In particular sparse data exists on the benefit 
of radiotherapy, and on the dose and technique required to 
achieve maximal benefit, with minimal toxicity. 
 
Material and Methods: Five patients with primary cardiac 
and great vessel sarcomas, diagnosed between 2010and 2013, 
were identified in our radiation oncology department 
database. 
We present here their clinical characteristics,dosimetric 
data, and outcomes. 
 
Results: All Patients analyzed had high grade sarcoma with 
various histologic subtypes and without metastatic 
spread.Sites of origin were left atrium (2), SVC, pulmonary 
artery and descending thoracic aorta.Four patients had 
positive margins after curative-intent surgery, while one was 
considered inoperable. Surgery included reconstruction with 
a graft in three cases (PTFE / Gore-Tex) and 
heartautotransplantation technique in one.One patient 
received neoadjuvant and adjuvant chemotherapy.All 
patients received fractionated radiotherapy utilizing IMRT 
with Simultaneous Integrated Boost (SIB) to a maximal dose 
of 60-65Gy, except for one who received 54 Gy utilizing a3D 
technique. Mean PTV was 419.23 (range: 163.99cm3-
631.95cm3).All patients completed the full course of 
treatment. Acute toxicity consisted mainly of fatigue and 
mild dysphagia, while long termevents were significant for 
NSTEMI in one patient (with local recurrence), and mild-
moderate pleural and pericardial effusions in another 
patient. With a median follow-up of 25 months (range:24-31), 
4/5 pts remain loco-regionally controlled (including the 
patient treated with definitive radiotherapy) and one had 
local recurrence (the patient who received 54Gy).One patient 
remains NED, three others developed metastatic disease, and 
one died of his local recurrent disease. 
 
Conclusion: Based on our experience, radiotherapy to a dose 
of 60-65Gy using IMRT/SIB can achieve very good local 
control in the adjuvant and possibly definitive setting in 
cardiac and large vessels HG sarcomas. This schedule is 
feasible and generally well tolerated. 
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Purpose or Objective: Proton beam therapy (PT) is an 
attractive tool in multimodality cancer care and of increasing 
interest especially for tumors in close proximity to critical 
structures or in particular sensitive tissues. First clinical 
results of patients with sarcomatous tumors treated at the 
West German Proton Therapy Center Essen (WPE) with regard 
to early toxicity are presented. 
 
Material and Methods: Between May 2013 and Oct 2015, 101 
patients (aged 0.9-84.6 y (median 13.8 y); 56% male) with 
sarcomas were prospectively enrolled in the registry studies 
“KiProReg” and “ProReg” at WPE. Histologies were 
rhabdomyosarcoma (n=38), chordoma/chondrosarcoma 
(n=28), EWING sarcoma (n=10), synovial sarcoma (n=4), 
osteosarcoma (n=3), malignant rhabdoid tumors (n=3), and 
miscellaneous (n=15). In 79% of the cohort, residual disease 
